RAYVEN
DEAD

Serial Number

88658332

Owner

ACTAVIS HOLDCO US, INC.

Attorney

Laurence Rickles

Filing Date

Oct 17, 2019

Add to watchlist:

No watchlists yet
View on USPTO

RAYVEN Trademark

Serial Number: 88658332

RAYVEN is a trademark filed by ACTAVIS HOLDCO US, INC. on October 17, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ACTAVIS HOLDCO US, INC. (65 trademarks)

PARSIPPANY, NJ 07054

Entity Type: 03

Trademark Details

Filing Date

October 17, 2019

Registration Date

Not Registered

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting the sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting the urogenital organs; Pharmaceuticals and medicines affecting the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 10, 2020 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 10, 2020 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 24, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jan 24, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jan 24, 2020 CNRT
ASSIGNED TO EXAMINER
Jan 23, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 22, 2019 NWOS
NEW APPLICATION ENTERED
Oct 21, 2019 NWAP